

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Proposed Single Technology Appraisal (STA)

#### Carfilzomib for treating multiple myeloma in people who have received at least 1 prior therapy [ID677]

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company(ies)</u></p> <ul style="list-style-type: none"> <li>• Amgen (carfilzomib)</li> </ul> <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer52</li> <li>• Equalities National Council</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Leukaemia Cancer Society</li> <li>• Leukaemia CARE</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Myeloma UK</li> <li>• Rarer Cancers Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Committee for Standards in Haematology</li> <li>• British Society for Haematology</li> <li>• British Geriatrics Society</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Research UK</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (doxorubicin)</li> <li>• Actavis UK (doxorubicin)</li> <li>• Aspen (melphalan)</li> <li>• Baxter (cyclophosphamide)</li> <li>• Celgene (lenalidomide, pomalidomide, thalidomide)</li> <li>• Cephalon (doxorubicin)</li> <li>• Genus Pharmaceuticals (vincristine)</li> <li>• Hameln Pharmaceuticals (dexamethasone)</li> <li>• Hospira (dexamethasone, doxorubicin, vincristine)</li> <li>• Janssen (bortezomib, doxorubicin)</li> <li>• Medac GmbH (doxorubicin)</li> <li>• Merck Sharp &amp; Dohme</li> </ul>

National Institute for Health and Care Excellence

Provisional matrix for the proposed single technology appraisal of carfilzomib for treating multiple myeloma in people who have received at least 1 prior therapy [ID677]

Issue date: November 2014

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Health Forum</li> <li>• UK Myeloma Forum</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS North Staffordshire CCG</li> <li>• NHS Richmond CCG</li> <li>• Welsh Government</li> </ul>	<p>(dexamethasone)</p> <ul style="list-style-type: none"> <li>• Napp pharmaceuticals (bendamustine)</li> <li>• Pfizer (cyclophosphamide, doxorubicin)</li> <li>• Rosemont Pharmaceuticals (dexamethasone)</li> <li>• Teva UK (doxorubicin, vincristine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Clinical Trials Research Unit</li> <li>• Cochrane Haematological Malignancies Group</li> <li>• Elimination of Leukaemia Fund</li> <li>• Institute of Cancer Research</li> <li>• Leukaemia and Lymphoma Research</li> <li>• Leuka</li> <li>• Leukaemia Busters</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> </ul> <p>National Institute for Health Research</p> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that manufacture comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.